Double-blind placebo-controlled study of mesalamine in post-infective irritable bowel syndrome – a pilot study

Tuteja, Ashok K.; Fang, John C.; Al-Suqi, Manal; Stoddard, Gregory J.; Hale, Devon C.

doi:10.3109/00365521.2012.694903

Cited by 41Gastrointestinal motility and disordersMicroscopic ColitisInflammatory Bowel Disease

Double-blind placebo-controlled study of mesalamine in post-infective irritable bowel syndrome – a pilot study

Tuteja, Ashok K., Fang, John C., Al-Suqi, Manal, Stoddard, Gregory J., Hale, Devon C.·2012·Scandinavian Journal of Gastroenterology

DOI 10.3109/00365521.2012.694903

Open this paper in CoChat — free account

Abstract

OBJECTIVE: Post-infective irritable bowel syndrome (PI-IBS) is characterized by continuing symptoms of irritable bowel syndrome, typically diarrhea-predominant, following an episode of acute gastroenteritis. There is often an increase in sub-epithelial inflammatory and neuroendocrine cells on colonic mucosal biopsy. Mesalamine is an anti-inflammatory agent, effective in the treatment of inflammatory bowel disease. The goal of this study was to compare mesalamine to placebo on symptoms and quality-of-life (QOL) in PI-IBS. MATERIAL AND METHODS: Twenty patients who developed diarrhea-predominant IBS after gastroenteritis were randomized to receive mesalamine (Asacol®) 1.6 gm b.i.d. or placebo for 12 weeks in a double-blind placebo-controlled study. QOL was assessed using the IBS-QOL questionnaire. Stool frequency, stool consistency, urgency, severity of abdominal pain, severity of bloating, and global-improvement scale were recorded in daily diaries for 7 days at baseline and every 4 weeks. Data were analyzed by comparing the change from baseline to last follow-up. RESULTS: One patient withdrew after randomization; data were incomplete in two patients. Thus, data were analyzed from 17 patients (11 men and 6 women, median age: 27 years, range 22-45 years). Mesalamine was not associated with significant improvement in global symptoms, abdominal pain, bloating, stool urgency, frequency, or consistency (all p ≥ 0.11) or QOL (p ≥ 0.16). CONCLUSIONS: There was no significant improvement in global symptoms or overall QOL with mesalamine in patients with PI-IBS.

Integrity signals

Registry

Crossref · 10.3109/00365521.2012.694903

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A small, double-blind, randomized study of 20 IBS patients showed that mesalamine 2.4 g/day for 8 wk failed to show improvement in IBS symptoms despite a reduction in the number of total immune cells in colonic biopsies and improvement in general well-being.
“A small, double-blind, randomized study of 20 IBS patients showed that mesalamine 2.4 g/day for 8 wk failed to show improvement in IBS symptoms despite a reduction in the number of total immune cells in colonic biopsies and improvement in general well-being (45, 177).”
From Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome (2013) · cites this paper as [177]

Nonparametric Statistics for the Behavioral Sciences
Guitton, H., & Siegel, S. (1958) · Revue économique · doi:10.2307/3498751 · Cited by 35,281 · see citing works
Functional Bowel Disorders
Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.061 · Cited by 4,856 · see citing works
Nonparametric Statistics : for the Behavioral Sciences
Siegel, S. (1956) · UCLA - Biblioteca de Ciencias y Tecnologia Felix Morales Bueno · Cited by 3,314 · see citing works
The SCL-90 and the MMPI: A Step in the Validation of a New Self-Report Scale
Derogatis, L. R., Rickels, K., & Rock, A. F. (1976) · British Journal of Psychiatry · doi:10.1192/bjp.128.3.280 · Cited by 2,298 · see citing works
Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute <i>Campylobacter</i> enteritis and in post-dysenteric irritable bowel syndrome
Spiller, R. C., Jenkins, D., Thornley, J. P., Hebden, J. M., Wright, T., Skinner, M., & Neal, K. R. (2000) · Gut · doi:10.1136/gut.47.6.804 · Cited by 1,155 · see citing works
Postinfectious Irritable Bowel Syndrome
Spiller, R., & Garsed, K. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.02.074 · Cited by 1,024 · see citing works
Activation of the mucosal immune system in irritable bowel syndrome
Chadwick, V. S., Chen, W., Shu, D., Paulus, B., Bethwaite, P., Tie, A., & Wilson, I. (2002) · Gastroenterology · doi:10.1053/gast.2002.33579 · Cited by 833 · see citing works
Healing and relapse of severe peptic esophagitis after treatment with omeprazole
Hetzel, D. J., Dent, J., REED, W. D., Narielvala, F. M., Mackinnon, M., McCarthy, J. H., Mitchell, B., Beveridge, B. R., Laurence, B. H., Gibson, G. E., et al. (1988) · Gastroenterology · doi:10.1016/0016-5085(88)90162-x · Cited by 775 · see citing works
The role of psychological and biological factors in postinfective gut dysfunction
Gwee, K.-A., Leong, Y.-L., Graham, C., McKendrick, M. W., Collins, S. M., Walters, S. J., Underwood, J. E., & Read, N. W. (1999) · Gut · doi:10.1136/gut.44.3.400 · Cited by 764 · see citing works
Quality of Life in Persons with Irritable Bowel Syndrome (Development and Validation of a New Measure)
Patrick, D. L., Drossman, D. A., Frederick, I. O., Dicesare, J., & Puder, K. L. (1998) · Digestive Diseases and Sciences · doi:10.1023/a:1018831127942 · Cited by 761 · see citing works
Immune Activation in Patients With Irritable Bowel Syndrome
Liebregts, T., Adam, B., Bredack, C., Röth, A., Heinzel, S., Lester, S., Downie–Doyle, S., Smith, E., Drew, P., Talley, N. J., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.01.046 · Cited by 660 · see citing works
Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator–activated receptor-γ
Rousseaux, C., Lefebvre, B., Dubuquoy, L., Lefèbvre, P., Romano, O., Auwerx, J. H., METZGER, D., Wahli, W., Desvergne, B., Naccari, G. C., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041948 · Cited by 528 · see citing works
THE IRRITABLE COLON SYNDROME
Chaudhary, N. A., & Truelove, S. C. (1962) · QJM · doi:10.1093/oxfordjournals.qjmed.a066971 · Cited by 498 · see citing works
Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire
Drossman, D. A., Patrick, D. L., Whitehead, W. E., Toner, B. B., Diamant, N. E., Hu, Y., Jia, H., & Bangdiwala, S. I. (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.01941.x · Cited by 424 · see citing works
Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome
Gwee, K.-A. (2003) · Gut · doi:10.1136/gut.52.4.523 · Cited by 415 · see citing works
Distinctive Clinical, Psychological, and Histological Features of Postinfective Irritable Bowel Syndrome
Dunlop, S. P., Jenkins, D., & Spiller, R. C. (2003) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07542.x · Cited by 359 · see citing works
Postinfectious irritable bowel syndrome1 1Abbreviations used in this paper: EC,_; IBS, irritable bowel syndrome; PI, postinfective.
Spiller, R. E. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00324-x · Cited by 353 · see citing works
Postinfectious Irritable Bowel Syndrome-A Meta-Analysis
Halvorson, H. A., Schlett, C. D., & Riddle, M. S. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00654.x · Cited by 352 · see citing works
Terminal ileal mucosal mast cells in irritable bowel syndrome
Weston, A. P., Biddle, W. L., Bhatia, P. S., & Miner, P. B. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01303164 · Cited by 338 · see citing works
Distribution of collagenous colitis: utility of flexible sigmoidoscopy.
Tanaka, M., Mazzoleni, G., & Riddell, R. H. (1992) · Gut · doi:10.1136/gut.33.1.65 · Cited by 218 · see citing works
Post-Diarrhea Chronic Intestinal Symptoms and Irritable Bowel Syndrome in North American Travelers to Mexico
Okhuysen, P. C., Jiang, Z. D., Carlin, L. G., Forbes, C., & DuPont, H. L. (2004) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.30435.x · Cited by 216 · see citing works
Review article: mode of action and delivery of 5‐aminosalicylic acid – new evidence
Desreumaux, P., & Ghosh, S. K. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03069.x · Cited by 199 · see citing works
Role of infection in irritable bowel syndrome
Spiller, R. C. (2007) · Journal of Gastroenterology · doi:10.1007/s00535-006-1925-8 · Cited by 187 · see citing works
The prevalence, anatomic distribution, and diagnosis of colonic causes of chronic diarrhea
Fine, K. D., Seidel, R. H., & Kim, Q. (2000) · Gastrointestinal Endoscopy · doi:10.1016/s0016-5107(00)70362-2 · Cited by 179 · see citing works
Randomized, double‐blind, placebo‐controlled trial of prednisolone in post‐infectious irritable bowel syndrome
Dunlop, S., Jenkins, D., Neal, K. R., Næsdal, J., Borgaonker, M., Collins, S. M., & Spiller, R. E. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01640.x · Cited by 178 · see citing works
Lymphocytic (microscopic) colitis
Giardiello, F. M., Lazenby, A. J., Bayless, T. M., Levine, E. J., Bias, W. Β., Ladenson, P. W., Hutcheon, D. F., Derevjanik, N. L., & Yardley, J. H. (1989) · Digestive Diseases and Sciences · doi:10.1007/bf01540051 · Cited by 165 · see citing works
Lymphocytic colitis: clinical presentation and long term course
Müllhaupt, B., Güller, U., Anabitarte, M., Güller, R., & Fried, M. (1998) · Gut · doi:10.1136/gut.43.5.629 · Cited by 135 · see citing works
Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof‐of‐concept study
CORINALDESI, R., STANGHELLINI, V., CREMON, C., GARGANO, L., COGLIANDRO, R. F., DE GIORGIO, R., BARTESAGHI, G., CANOVI, B., & BARBARA, G. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04041.x · Cited by 131 · see citing works
Post-Traveler's Diarrhea Irritable Bowel Syndrome: A Prospective Study
Ilnyckyj, A., Balachandra, B., Elliott, L. J., Choudhri, S., & Duerksen, D. R. (2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07297.x · Cited by 97 · see citing works
Microscopic colitis: prevalence and distribution throughout the colon in patients with chronic diarrhoea.
Thijs, W., van Baarlen, J., KLEIBEUKER, J. H., & Kolkman, J. J. (2005) · PubMed · Cited by 77 · see citing works
Postinfectious Irritable Bowel Syndrome
Barbara, G., Cremon, C., Pallotti, F., GIORGIO, R. D., Stanghellini, V., & Corinaldesi, R. (2009) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e3181a15e2e · Cited by 66 · see citing works
An Exact and a Monte Carlo Proposal to the Fisher–Pitman Permutation Tests for Paired Replicates and for Independent Samples
Kaiser, J. (2007) · The Stata Journal Promoting communications on statistics and Stata · doi:10.1177/1536867x0700700307 · Cited by 58 · see citing works
Development of Functional Diarrhea, Constipation, Irritable Bowel Syndrome, and Dyspepsia During and After Traveling Outside the USA
Tuteja, A. K., Talley, N. J., Gelman, S. S., Adler, S. C., Thompson, C. M., Tolman, K., & Hale, D. C. (2007) · Digestive Diseases and Sciences · doi:10.1007/s10620-007-9853-x · Cited by 51 · see citing works
Self-citation

Flagged first, then by citations

Sorted by citations

Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome
Barbara, G., Grover, M., Berčík, P., Corsetti, M., Ghoshal, U. C., Öhman, L., & Rajilić-Stojanović, M. D. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.07.011 · Cited by 283 · see citing works
Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility
Savarino, E., Zingone, F., Barberio, B., Marasco, G., Akyuz, F., Akpınar, H., Bărboi, O., Bodini, G., Bor, S., Chiarioni, G., et al. (2022) · United European Gastroenterology journal · doi:10.1002/ueg2.12259 · Cited by 136 · see citing works
Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome
Ringel, Y., & Maharshak, N. (2013) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00207.2012 · Cited by 115 · see citing works
Mast cell mediation of visceral sensation and permeability in irritable bowel syndrome
Hasler, W. L., Grabauskas, G., Singh, P., & Owyang, C. (2022) · Neurogastroenterology & Motility · doi:10.1111/nmo.14339 · Cited by 105 · see citing works
A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D)
Lam, C., Tan, W., Leighton, M., Hastings, M. C., Lingaya, M. R., Falcone, Y., Zhou, X., Xu, L., Whorwell, P. J., Walls, A. F., et al. (2015) · Gut · doi:10.1136/gutjnl-2015-309122 · Cited by 92 · see citing works
Pharmacological Approach for Managing Pain in Irritable Bowel Syndrome: A Review Article
Chen, L., Ilham, S., & Feng, B. (2017) · Anesthesiology and Pain Medicine · doi:10.5812/aapm.42747 · Cited by 73 · see citing works
Update S3-Leitlinie Reizdarmsyndrom: Definition, Pathophysiologie, Diagnostik und Therapie. Gemeinsame Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Neurogastroenterologie und Motilität (DGNM) – Juni 2021 – AWMF-Registriernummer: 021/016
Layer, P., Andresen, V., Allescher, H. ‐., Bischoff, S. C., Claßen, M., Elsenbruch, S., Freitag, M., Frieling, T., Gebhard, M., Goebel‐Stengel, M., et al. (2021) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1591-4794 · Cited by 78 · see citing works
Experimental Models of Irritable Bowel Syndrome and the Role of the Enteric Neurotransmission
Vannucchi, M. G., & Evangelista, S. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7010004 · Cited by 75 · see citing works
Systematic review: instruments to assess abdominal pain in irritable bowel syndrome
Mujagic, Z., Keszthelyi, D., Aziz, Q., Reinisch, W., Quetglas, E. G., Leonardis, F. D., Segerdahl, M., & Masclee, A. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13378 · Cited by 64 · see citing works
Post-infection Irritable Bowel Syndrome
Berumen, A., Edwinson, A. L., & Grover, M. (2021) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2021.02.007 · Cited by 60 · see citing works
Treatment of abdominal pain in irritable bowel syndrome
Vanuytsel, T., Tack, J. F., & Boeckxstaens, G. E. (2014) · Journal of Gastroenterology · doi:10.1007/s00535-014-0966-7 · Cited by 51 · see citing works
Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome
Camilleri, M. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.794223 · Cited by 50 · see citing works
Emerging role of the gut microbiome in post-infectious irritable bowel syndrome: A literature review
Lupu, V. V., Ghiciuc, C. M., Ștefănescu, G., Mihai, C. M., Popp, A., Săsăran, M. O., Bozomitu, L. I., Stârcea, I. M., Răileanu, A. A., & Lupu, A. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i21.3241 · Cited by 50 · see citing works
Biomarkers as a diagnostic tool for irritable bowel syndrome: where are we?
Camilleri, M., Halawi, H., & Oduyebo, I. (2017) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2017.1288096 · Cited by 45 · see citing works
Pharmacologic, Pharmacokinetic, and Pharmacogenomic Aspects of Functional Gastrointestinal Disorders
Camilleri, M., Bueno, L. P., Andresen, V., Ponti, F. D., Choi, M., & Lembo, A. J. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.029 · Cited by 43 · see citing works
Pharmacological agents currently in clinical trials for disorders in neurogastroenterology
Camilleri, M. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70837 · Cited by 32 · see citing works
Role of gut pathogens in development of irritable bowel syndrome.
Grover, M. (2014) · Europe PMC (PubMed Central) · Cited by 31 · see citing works
Identifying, Understanding, and Managing Fecal Urgency in Inflammatory Bowel Diseases
Caron, B., Ghosh, S. K., Danese, S., & Peyrin‐Biroulet, L. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.02.029 · Cited by 32 · see citing works
Changes of excitatory and inhibitory neurotransmitters in the colon of rats underwent to the wrap partial restraint stress
Traini, C., Evangelista, S., Girod, V., Faussone‐Pellegrini, M. S., & Vannucchi, M. G. (2016) · Neurogastroenterology & Motility · doi:10.1111/nmo.12816 · Cited by 28 · see citing works
Systematic Review and Meta-analysis: Efficacy of Mesalamine in Irritable Bowel Syndrome
Goodoory, V. C., Tuteja, A. K., Black, C. J., & Ford, A. C. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.02.014 · Cited by 28 · see citing works
Self-citation
Recent advances in pharmacological treatment of irritable bowel syndrome.
Lazaraki, G., Chatzimavroudis, G., & Katsinelos, P. (2014) · PubMed Central · doi:10.3748/wjg.v20.i27.8867 · Cited by 25 · see citing works
Consenso mexicano sobre el síndrome de intestino irritable
Carmona-Sánchez, R., Icaza-Chávez, M. E., Bielsa-Fernández, M. V., Gomez-Escudero, O., Bosques‐Padilla, F., Coss‐Adame, E., Esquivel-Ayanegui, F., Flores-Rendón, Á. R., González-Martínez, M. A., Huerta-Iga, F. M., et al. (2016) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2016.01.004 · Cited by 24 · see citing works
Current and Emerging Pharmacotherapeutic Options for Irritable Bowel Syndrome
Barboza, J., Talley, N. J., & Moshiree, B. (2014) · Drugs · doi:10.1007/s40265-014-0292-7 · Cited by 24 · see citing works
Role of inflammation in pediatric irritable bowel syndrome
Nardo, G. D., Cremon, C., Staiano, A., Stanghellini, V., Borrelli, O., Strisciuglio, C., Romano, C., Mallardo, S., Scarpato, E., Marasco, G., et al. (2022) · Neurogastroenterology & Motility · doi:10.1111/nmo.14365 · Cited by 21 · see citing works
The Mexican consensus on irritable bowel syndrome
Carmona-Sánchez, R., Icaza-Chávez, M. E., Bielsa-Fernández, M. V., Gomez-Escudero, O., Bosques‐Padilla, F., Coss‐Adame, E., Esquivel-Ayanegui, F., Flores-Rendón, Á. R., González-Martínez, M. A., Huerta-Iga, F. M., et al. (2016) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2016.01.004 · Cited by 18 · see citing works
Belgian consensus on irritable bowel syndrome
Kindt, S., Louis, H., Schepper, H. U. D., Arts, J., Caenepeel, P., Looze, D. A. D., Gerkens, A., Holvoet, T., Latour, P., Mahler, T., et al. (2022) · Acta gastro-enterologica belgica · doi:10.51821/85.2.10100 · Cited by 18 · see citing works
Effectiveness of mesalazine to treat irritable bowel syndrome
Zhang, F., Li, S., Ding, L., Xiang, S.-H., Zhu, H.-T., Yu, J., & Xu, G. (2019) · Medicine · doi:10.1097/md.0000000000016297 · Cited by 16 · see citing works
Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): study protocol for a randomised controlled trial
Leighton, M., Lam, C., Mehta, S. P., & Spiller, R. E. (2013) · Trials · doi:10.1186/1745-6215-14-10 · Cited by 12 · see citing works
Randomised clinical trial and meta‐analysis: mesalazine treatment in irritable bowel syndrome—effects on gastrointestinal symptoms and rectal biomarkers of immune activity
Tejera, V. C., Öhman, L., Aabakken, L., Fellström, B., Hausken, T., Hovde, Ø., Hreinsson, J. P., Lindberg, G., Venge, P., Simrén, M., et al. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17182 · Cited by 10 · see citing works
Condition‐specific role of colonic inflammatory molecules in persistent functional colorectal hypersensitivity in the mouse
La, J., & Gebhart, G. F. (2014) · Neurogastroenterology & Motility · doi:10.1111/nmo.12455 · Cited by 8 · see citing works
Interventions for post-infectious irritable bowel syndrome: a systematic review of treatment efficacy
Torbicki, E., Oh, J., Mishra, S., Page, A. V., & Boggild, A. K. (2015) · Tropical Diseases Travel Medicine and Vaccines · doi:10.1186/s40794-015-0002-9 · Cited by 6 · see citing works
Evolving Molecular Targets in the Treatment of Nonmalignant Gastrointestinal Diseases
Katzka, D. A., Loftus, E. V., & Camilleri, M. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.77 · Cited by 6 · see citing works
Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): a multicentre, parallel-group, randomised placebo-controlled trial
Lam, C., Tan, W., Leighton, M., Hastings, M. C., Lingaya, M. R., Falcone, Y., Zhou, X., Xu, L., Whorwell, P. J., Walls, A. F., et al. (2015) · Efficacy and Mechanism Evaluation · doi:10.3310/eme02020 · Cited by 5 · see citing works
Significance of Postinfectious Irritable Bowel Syndrome?
Spiller, R. E. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.11.034 · Cited by 5 · see citing works
Randomized double‐blind placebo‐controlled study to evaluate the effect of long‐acting mesalamine on postinfectious irritable bowel syndrome with diarrhea
Tuteja, A. K., Leung, D. T., Fang, J. C., Talley, N. J., & Stoddard, G. J. (2024) · Neurogastroenterology & Motility · doi:10.1111/nmo.14889 · Cited by 5 · see citing works
Self-citation
Immune activation in irritable bowel syndrome: from basic to clinic
Bashashati, M. (2017) · NeuroGastroLATAM Reviews · doi:10.24875/ngl.m17000002 · Cited by 3 · see citing works
Efecto de la administración oral del agente estabilizador del mastocito, cromoglicato disódico, sobre la evolución clínica y biológica en pacientes con síndrome del intestino irritable con predominio de diarrea
Lobo, B. (2013) · TDX (Tesis Doctorals en Xarxa) · Cited by 1 · see citing works
Inflammation as a Potential Therapeutic Target in IBS
Chira, A., Chira, R. I., & Dumitrascu, D. L. (2016) · InTech eBooks · doi:10.5772/66193
El mastocito: célula clave en la microinflamación intestinal y en la regulación de la función barrera mediada por el estrés en el síndrome del intestino irritable con predominio de diarrea
Guilarte, M. (2014) · TDX (Tesis Doctorals en Xarxa)
Postinfection irritable bowel syndrome
Marcellini, M. M., Barbaro, M. R., Cremon, C., & Barbara, G. (2018) · NeuroGastroLATAM Reviews · doi:10.24875/ngl.18000012
Infections Associated With Irritable Bowel Syndrome
Gurunathan, S. V., & Grover, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-54843-4.00007-6

Double-Blind Placebo Controlled Study of mesalamine in Post-Infective Irritable Bowel Syndrome
Tuteja, A. K., Hale, D. C., Stoddard, G. J., Fang, J. C., & Tolman, K. (2008) · The American Journal of Gastroenterology · doi:10.14309/00000434-200809001-01227 · Cited by 2 · see citing works
Self-citation
Randomized double‐blind placebo‐controlled study to evaluate the effect of long‐acting mesalamine on postinfectious irritable bowel syndrome with diarrhea
Tuteja, A. K., Leung, D. T., Fang, J. C., Talley, N. J., & Stoddard, G. J. (2024) · Neurogastroenterology & Motility · doi:10.1111/nmo.14889 · Cited by 5 · see citing works
Self-citation
Mo1561 THE EFFECT OF LONG-ACTING MESALAMINE OF POST-INFECTIOUS IRRITABLE BOWEL SYNDROME
Tuteja, A. K., Talley, N. J., Fang, J. C., Leung, D. T., & Stoddard, G. (2020) · Gastroenterology · doi:10.1016/s0016-5085(20)32926-7 · Cited by 1 · see citing works
Self-citation
Tolerability and effect of mesalazine in postinfectious irritable bowel syndrome
Hanevik, K., Dizdar, V., Langeland, N., Eide, G. E., & Hausken, T. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04715.x · Cited by 10 · see citing works
Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine
Bafutto, M., de Almeida, J. R., Leite, N. V., de Oliveira, Ê. C., Neto, S. G., & Rezende-Filho, J. (2011) · Arquivos de Gastroenterologia · doi:10.1590/s0004-28032011000100008 · Cited by 26 · see citing works

Authors: Tuteja, A. K., Fang, J. C., Al-Suqi, M., Stoddard, G. J., & Hale, D. C.
Affiliations: University of Utah (US)
George E. Wahlen Department of VA Medical Center (US)
Corresponding author: Tuteja, Ashok K.
ORCID: Tuteja, Ashok K.
Fang, John C.
Stoddard, Gregory J.
Venue: Scandinavian Journal of Gastroenterology
Publisher: Informa UK Limited
Published: 2012-07-12
Volume: 47
Issue: 10
Pages: 1159-1164
ISSN: 0036-5521 (ISSN-L)
1502-7708
DOI: 10.3109/00365521.2012.694903
OpenAlex: W2077139557
Cited by: 41
References: 33
Citations by year: 2024: 1 · 2023: 3 · 2022: 5 · 2021: 2 · 2019: 2 · 2018: 4 · 2017: 3 · 2016: 5 · 2015: 4 · 2014: 6 · 2013: 5 · 2012: 1
FWCI: 4.97
Type: journal article
Language: en
Open access: closed
Locations: Scandinavian Journal of Gastroenterology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
Health Sciences › Medicine › Epidemiology › Microscopic Colitis
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Inflammatory Bowel Disease
Keywords: 5-aminosalicylic acid, anti-inflammatory therapy, acute gastroenteritis, diarrhea-predominant irritable bowel syndrome, quality of life, abdominal pain, bloating, colonic mucosal inflammation
MeSH terms: Acute Disease, Adult, Anti-Inflammatory Agents, Non-Steroidal, Biopsy, Diarrhea, Double-Blind Method, Female, Gastroenteritis, Humans, Intestinal Mucosa, Male, Pain Measurement, Pilot Projects, Quality of Life, Surveys and Questionnaires, Severity of Illness Index, Abdominal Pain, Treatment Outcome, Mesalamine, Irritable Bowel Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Double-blind placebo-controlled study of mesalamine in post-infective irritable bowel syndrome – a pilot study

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks